Roth "FDA decision helps ACAD valuation in 4 ways.....Increasing Target to $20"..
Roth "FDA decision helps ACAD valuation in 4 ways. Pim to be widely prescribed, incl off-label Alzheimers given clean label - peak sales reaching well over $1 billion...Increasing Target to $20"...
Full rpt doesnt post on yahoo - this and other full reports on Investorvillage ACAD board
Roth Capital Partners, LLC
Estimates Changed, Target Price Increased
12-Mo.Price Target $20.00
ACAD: Pimavanserin Development Accelerates
After meeting with FDA, based on the strength and consistency of the results for pimavanserin in the 020 study, another Phase 3 study is not necessary for its filing for psychosis related to Parkinson's disease. This moves forward pimavanserin's estimated approval to late 2015, and increases the possibility of a takeover of Acadia, given the scarcity of meaningful CNS assets. We reiterate our Buy and raise our ACAD target to $20.
Important Progress for Pimavanserin: No Additional Phase 3 Needed.
After a meeting with FDA, Acadia management has determined that based on the strength of the recent Phase 3 results onm study 020 for pimavansein in Parkinson's psychosis, another Phase 3 study is not necessary. This positive and rare occurrence is based on the strength of the therapy's 020 study, which was a large multicenter study, that demonstrated strong, consistent data across a number of metrics.
Pimavanserin's 020 Study Results Lead to Early Consideration by FDA.